DXR earnings: next report 2026-08-20, real EPS beat/miss history, analyst consensus Buy, P/E 5.90. Updated 2026-07-23.
Daxor (DXR) Research Hub
Daxor (DXR) trades on NASDAQ, US in the Healthcare (Medical - Instruments & Supplies) sector. As of 2026-09-11, shares last closed at 11.47 USD (+5.71%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E 5.90, market cap 0.05B. This hub links to the full technical, earnings and options research available for DXR.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Medical - Instruments & Supplies) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 11.47 USD (+5.71%) |
| 52-week range | 9.4 USD – 11.47 USD |
| Trend regime | Range |
| 14-day RSI | 68.8 (Bullish) |
| Trailing P/E | 5.90 |
| Market cap | 0.05B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-20 |
Available research for DXR
Covered Call on DXR: how it works, illustrative setup around the real 11.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on DXR: how it works, illustrative setup around the real 11.47 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on DXR: how it works, illustrative setup around the real 11.47 USD price, max profit/loss, breakeven and when to use it. Educational.
DXR technical analysis: range, last 11.47 USD, RSI 68.8, 52w range 9.4 USD–11.47 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is DXR in?
Daxor (DXR) is classified under Healthcare (Medical - Instruments & Supplies), listed on NASDAQ, US.
Is DXR in an uptrend or downtrend?
As of 2026-09-11, DXR is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is DXR's trailing P/E ratio?
DXR's trailing P/E is 5.90, with a market cap of 0.05B. See the earnings research page for full valuation detail.
When does DXR next report earnings?
DXR is next scheduled to report earnings on 2026-08-20, with a consensus EPS estimate of -0.11 USD.